… shown to be effective in patients with cytokine storm syndromes [Citation66], and further …
alternative for the treatment of cytokine release syndrome in patients with COVID-19 [Citation67]. …

… East respiratory syndrome–coronavirus (MERS-CoV), SARS-CoV-2 is the third coronavirus
to cause severe respiratory illness in humans, called coronavirus disease 2019 (COVID-19). …

… Given the efficacy of tocilizumab in CRS and the pivotal role of IL-6 in COVID-19, we propose
to repurpose tocilizumab to treat severe cases of COVID-19. Regarding its clinical use, we …

… All longitudinal data are shown with respect to the date of COVID-19 symptom onset (D0).
Red stars denote the days on which levels of cytokine release syndrome-related inflammatory …

… a reasonable hypothesis that cytokine storms play an important role in severe COVID-19
cases. Therefore, neutralising key inflammatory factors in cytokine release syndrome (CRS) will …

… immune response characterized by an upregulation of pro-inflammatory cytokines, resembling
the clinical and serological features of cytokine release syndrome (CRS). CRS is a life-…

… of these severe manifestations of COVID-19 is cytokine release syndrome (CRS) and its …
These syndromes are characterized by an excessive production of inflammatory cytokines (IL-6, …

… respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with
severe coronavirus disease 2019 (COVID-19) might experience cytokine release syndrome (…

… However, approximately 1 month after the COVID-19 peak in … healthy children with COVID-19
infection confirmed by serologic … with COVID-19 post-infectious cytokine release syndrome. …

… cytokine release syndrome as observed in COVID-19 patients that may require targeting
of cytokine pathways, particularly IL-6-… COVID-19, which is a cytokine release syndrome (CRS). …